ELIGARD® (Leuprolide Acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer


You May Also Like

Paratek Announces FDA Advisory Committee Date for Omadacycline

BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company ...